Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.

@article{Hirotsu2017IntrinsicHV,
  title={Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.},
  author={Yosuke Hirotsu and Hiroshi Nakagomi and Kenji Amemiya and Toshio Oyama and Masayuki Inoue and Hitoshi Mochizuki and Masao Omata},
  journal={Medical oncology},
  year={2017},
  volume={34 1},
  pages={3}
}
HER2 (ERBB2) is an oncogene and 20% of breast cancers display HER2 amplification. The HER2 monoclonal antibody, trastuzumab, is used to treat breast cancers that display HER2 amplification, with good responses in 80-90% of cases; however, 10% of tumours develop resistance to trastuzumab. In this study, we collected data of primary breast cancer patients who treated at hospital during 2004-2014. In our cohort, 205 of 1497 primary breast cancer patients showed HER2-amplification, and 20… CONTINUE READING